Amidine-based bioactive compounds for the regulation of arginine metabolism

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1305-1310

  Maccallini, Cristina ^a   Fantacuzzi, Marialuigia ^a   Amoroso, Rosa ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Amidines; Dimethylarginine dimethylaminohydrolase (DDAH); Nitric oxide synthase (NOS); Peptidylarginine deiminase (PAD)

Indexed keywords

AMIDINE; ARGININE; DIMETHYLARGININASE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE DEIMINASE;

ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; CATALYSIS; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG POTENCY; HUMAN; IC 50; INFLAMMATORY DISEASE; METABOLISM; NEUROPATHY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

AMIDINES; ARGININE; HUMANS;

EID: 84881486465     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313090005     Document Type: Article

References (54)

1. Borders Jr., C.L.; Broadwater, J.A.; Bekeny, P.A.; Salmon, J.E.; Lee, A.S.; Eldridge, A.M.; Pett, V.B. A structural role for arginine in proteins: multiple hydrogen bonds to backbone carbonyl oxygens. Protein Sci., 1994, 3, 541-548.
2. Tapiero, H.; Mathé, G.; Couvreur, P.; Tew, K.D.I. Arginine. Biomed. Pharmacother., 2002, 56, 439-445
3. Granik, V.G. Molecular-biological problems of drug design and mechanism of drug action: metabolism of L-arginine (a review). Pharm. Chem., J. 2003, 37, 111-127
4. Tong, B.C.; Barbul, A. Cellular and physiological effects of arginine. Mini-Rev. Med. Chem., 2004, 4, 823-832
5. Morris Jr., S.M. Recent advances in arginine metabolism. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7, 45-51
6. Wu, G.; Fuller W. Bazer, F.W.; Davis, T.A.; Jaeger, L.A.; Johnson, G.A.; Kim, S.W.; Knabe D.A.; Meininger, C.J.; Spencer, T.E.; Yin, Y-L. Important roles for the arginine family of amino acids in swine nutrition and production. Livestock Science, 2007, 112, 8-22.
7. Frédérick, R.; Pochet, L.; Charlier, C.; Masereel, B. Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex. Curr. Med. Chem., 2005, 12, 397-417.
8. Topf, M.; Várnai, P.; Schofield, C.J.; Richards, W.G. Molecular dynamics simulations of the acyl-enzyme and the tetrahedral intermediate in the deacylation step of serine proteases. Protein. Struct. Funct. Genet., 2002, 47, 357-369.
9. Hrabák, A. Common ligands of G-protein-coupled receptors and arginine-utilizing enzymes. Br. J. Pharmacol., 2006, 147, 835-837
10. Deutz, N.E.P. 2007 The ESPEN Sir David Cuthbertson lecture: amino acids between and within organs. The glutamate-glutaminecitrulline- arginine pathway. Clin. Nutr., 2008, 27, 321-327.
11. Mašič, L.P. Arginine mimetic structures in biologically active antagonists and inhibitors. Curr. Med. Chem., 2006, 13, 3627-3648.
12. ω-arginine dimethylation modulates the interaction between a Gly/Arg-rich peptide from human nucleolin and nucleic acids. J. Pept. Res., 2000, 55, 348-358
13. Orwig, K.S.; Dix, T.A. Synthesis of Cα methylated carboxylic acids: isosteres of arginine and lysine for use as N-terminal capping residues in polypeptides. Tetr. Lett., 2005, 46, 7007-7009.
14. Webb, T.R.; Eigenbrot, C. Conformationally restricted arginine analogues. J. Org. Chem., 1991, 56, 3009-3016
15. Revilla-López, G.; Torras, J.; Jiménez, A.I.; Cativiela, C.; Nussinov, R.; Alemán, C. Side-chain to backbone interactions dictate the conformational preferences of a cyclopentane arginine analogue. J. Org. Chem., 2009, 74, 2403-2412
16. Watanabe, M.; Yamaguchi, K.; Tang, W.; Yoshida, K.; Silverman, R.B.; Arisawa, M.; Shuto, S. Synthesis of a series of 3,4-methanoarginines as side-chain conformationally restricted analogues of arginine. Bioorg. Med. Chem., 2011, 19, 5984-5988.
17. Baettig, U.; Brown, L.; Brundish, D.; Dell, C.; Furzer, A.; Garman, S.; Janus, D.; Kane, P.D.; Smith, G.; Walker, C.V.; Cockcroft, X.; Ambler, J.; Mitchelson, A.; Talbot, M.D.; Tweed, M.; Wills, N. The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position. Bioorg. Med. Chem. Lett., 2000, 10, 1563-1566
18. Schmuck, C.; Geiger, L. Design and synthesis of a new class of arginine analogues with an improved anion binding site in the side chain. Chem. Comm., 2005, 6, 772-774
19. Flemer Jr., S.; Madalengoitia, J.S. On-resin synthesis of novel arginine-isostere peptides bearing substituted amidine headgroups. J. Pept. Sci., 2012, 18, 30-36.
20. Maddaford, S.; Annedi, S.C.; Ramnauth, J.; Rakhit, S. Advancements in the development of nitric oxide synthase inhibitors. Annu. Rep. Med. Chem., 2009, 44, 27-50.
21. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J., 2001, 357, 593-615
22. Li, H.; Poulos, T.L. Structure-function studies on nitric oxide synthases. J. Inorg. Biochem., 2005, 99, 293-305.
23. Tinker, A.C.; Wallace, A.V Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr. Top. Med. Chem., 2006, 6, 77-79
24. Zhou., L.; Zhu, D.Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide, 2009, 20, 223-230
25. Muscara, M.N.; Wallace, J.L. Nitric oxide v. therapeutic potential of nitric oxide donors and inhibitors. Am. J. Physiol., 1999, 276, 1313-16.
26. Garvey, E.P.; Oplinger, J.A.; Furfine, E.S.; Kiff, R.J.; Laszlo, F.; Whittle, B.J.R.; Knowles, R.G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J. Biol. Chem., 1997, 272, 4959-4963.
27. Xue, F.; Kraus, J.M.; Labby, K.J.; Ji, H.; Mataka, J.; Xia, G.; Li, H.; Delker, S.L.; Roman, L.J.; Martásek, P.; Poulos, T.L.; Silverman, R.B. Improved synthesis of chiral pyrrolidine inhibitors and their binding properties to neuronal nitric oxide synthase. J. Med. Chem., 2011, 54, 2039-2048.
28. Ji, H.; Li, H.; Flinspach, M.; Poulos, T.L.; Silverman, R.B. Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. J. Med. Chem., 2003, 46, 5700-5711.
29. Zhu, Y.; Nikolic, D.; Van Breemen, R.B.; Silverman, R.B. Mechanism of inactivation of inducible nitric oxide synthase by amidines. Irreversible enzyme inactivation without inactivator modification. J. Am. Chem. Soc., 2005, 127, 858-868.
30. Pharmacia Corp. 2007, US196118 and WO2007203823.
31. Maccallini, C.; Patruno, A.; Besker, N.; Ali, J.I.; Ammazzalorso, A.; De Filippis, B.; Franceschelli, S.; Giampietro, L.; Pesce, M.; Reale, M.; Tricca, M.L.; Re, N.; Felaco, M.; Amoroso, R. Synthesis, biological evaluation, and docking studies of Nsubstituted acetamidines as selective inhibitors of inducible nitric oxide synthase. J. Med. Chem., 2009, 52, 1481-1485
32. Maccallini, C.; Patruno, A.; Lannutti, F.; Ammazzalorso, A.; De Filippis, B.; Franceschelli, S.; Fantacuzzi, M.; Giampietro, L.; Masella, S.; Felaco, M.; Re, N.; Amoroso, R. N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioor. Med. Chem. Lett., 2010, 20, 6495-6499
33. Fantacuzzi, M.; Maccallini, C.; Lannutti, F.; Patruno, A.; Masella, S.; Pesce, M.; Speranza, L.; Ammazzalorso, A.; De Filippis, B.; Giampietro, L.; Re, N.; Amoroso, R. Selective Inhibition of iNOS by benzyl- and dibenzyl derivatives of N-(3-aminobenzyl)acetamidine. ChemMedChem, 2011, 6, 1203-1206.
34. Fedorov R.;Hartmann, E.; Ghosh, D.K.; Schlichting, I. Structural basis for the specifity of the nitric-oxide synthase inhibitors W1400 and N_-Propyl-L-Arg for the inducible and neuronal isoforms. J. Biol.Chem., 2003, 278, 45818-45825.
35. Neuraxon Inc. US20060258721, 2006; WO2007118314, 2007; WO2009062318 and WO2009062319, 2009, WO2010132072, 2010.
36. Mladenova, G.; Annedi, S.C.; Ramnauth, J.; Maddaford, S.P.; Rakhit, S.; Andrews, J.S., Zhang, D., Porreca, F. First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain J. Med. Chem. 2012, 55, 3488-3505
37. Annedi, S.C.; Ramnauth, J.; Maddaford, S.P.; Renton, P.; Rakhit, S.; Mladenova, G.; Dove, P.; Silverman, S.; Andrews, J.S.; Di Felice M.; Porreca, F. Discovery of cis-N-(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene-2- carboximidamide: a 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities J. Med. Chem., 2012, 55, 943-955.
38. Ramnauth, J.; Renton, P.; Dove, P.; Annedi, S.C.; Speed, J.; Silverman, S.; Mladenova, G.; Maddaford, S.P.; Zinghini, S.; Rakhit, S.; Andrews, J.S; Lee, D.K.H.; Zhang, D.; Porreca., F. 1,2,3,4-Tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)- 1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a preclinical development candidate. J. Med. Chem., 2012, 55, 2882-2893
39. Renton, P.; Green, B.; Maddaford, S.P; Rakhit, S.; Andrews, J.S. NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity. ACS Med. Chem. Lett., 2012, 3, 227-231
40. Neuraxon Inc. WO2010000073, 2010.
41. Pope, A.J.; Karuppiah, K.; Cardounel, A.J. Role of the PRMTDDAH- ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol. Res., 2009, 60, 461-465
42. Teerlink, T.; Luo, Z.; Palm, F.; Wilcox, C.S. Cellular ADMA: regulation and action. Pharmacol. Res., 2009, 60, 448-460.
43. Tran, C.T.L.; Leiper, J.M.; Vallance, P. The DDAH/ADMA/NOS pathway. Atherosclerosis Supp. 2003, 4, 33-40
44. Palm, F.; Onozato, M.L.; Luo, Z.; Wilcox, C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H3227-H3245.
45. Leiper, J.; Nandi, M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis Nat. Rev. Drug Discov., 2011, 10, 277-291.
46. Kotthaus, J.; Schade, D.; Muschick, N.; Beitz, E.; Clement, B. Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenylamidines as new leads. Bioorg. Med. Chem., 2008, 16, 10205-10209.
47. Wang, J.; Mozingo, A.F.; Hu, S.; Schaller, T.H.; Robertus, J.D.; Fast, W. Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochem., 2009, 48, 8624-8635.
48. Lluis, M.; Wang, J.; Mozingo, A. F.; Fast, W; Robertus, J. D. Characterization of Calkyl amidines as bioavailable covalent reversible inhibitors of human DDAH-1. ChemMedChem, 2011, 6, 81-88.
49. Vossenaar, E.R.; Zendman, A.J.W.; van Venrooij, W.J.; Pruijn, G.J.M. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays, 2003, 25, 1106-1118.
50. Shirai, H.; Blundell, T.L.; Mizuguchi, K. A novel superfamily of enzymes that catalyze the modification of guanidino groups. Trends Biochem. Sci., 2001, 26, 465-468.
51. Luo, Y.; Arita, K.; Bhatia, M.; Knuckley, B.; Lee, Y.; Stallcup, M.R.; Sato, M.; Thompson, P.R. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry, 2006, 45, 11727-11736.
52. Gyorgy, B.; Toth, E.; Tarcsa, E.; Falus, A.; Buzas, E.I. Citrullination: A posttranslational modification in health and disease. Int. J. Biochem. Cell Biol., 2006, 38, 1662-1677.
53. 5-(2-chloro-1-iminoethyl)-L-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors. J. Med. Chem., 2011, 54, 6919-6935.
54. Knuckley, B.; Causey, C.P.; Jones, J.E.; Bhatia, M.; Dreyton, C.J.; Osborne, T.C.; Takahara, H.; Thompson, P.R. Substrate Specificity and Kinetic Studies of PADs 1, 3, and 4 Identify Potent and Selective Inhibitors of Protein Arginine Deiminase 3. Biochemistry, 2010, 49, 4852-4863.